Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer.
10.3802/jgo.2014.25.2.130
- Author:
Ho Suap HAHN
1
;
Ki Heon LEE
;
In Ho LEE
;
Jae Ho LEE
;
Chang Sung WHANG
;
Yeong Woo JO
;
Tae Jin KIM
Author Information
1. Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine, Seoul, Korea. kimonc@hotmail.com
- Publication Type:Original Article
- Keywords:
Chemotherapy;
DHP107;
Oral paclitaxel;
Ovarian cancer
- MeSH:
Animals;
Drug Therapy;
Female;
Humans;
Mice*;
Mice, Nude;
Ovarian Neoplasms*;
Paclitaxel*;
Tumor Burden
- From:Journal of Gynecologic Oncology
2014;25(2):130-135
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The purpose of this study was to compare the in vivo anti-tumor efficacy of a mucoadhesive, lipid-based, oral paclitaxel formulation (DHP107) with traditional, intraperitoneal (IP) paclitaxel using an orthotopic mouse model of chemotherapy-sensitive SKOV3ip1 ovarian cancer. METHODS: To determine the optimal therapeutic dose of oral paclitaxel, DHP107 was administered per os to female athymic nude mice at 0, 25, or 50 mg/kg twice per week. Control mice received 100 microL saline once per week. IP injections of paclitaxel at 5 mg/kg once per week were used for comparison. To evaluate the potential therapeutic effect of metronomic DHP107 chemotherapy, mice received DHP107 50 mg/kg once per week per os, which was compared with 25 mg/kg twice per week and with vehicle-treated controls. RESULTS: Low-dose DHP107 (25 mg/kg) twice per week was as effective as IP paclitaxel (5 mg/kg once a week) but high-dose DHP107 (50 mg/kg once per week) was less effective at inhibiting tumor growth in an orthotopic mouse model (88%, 82%, and 36% decrease in tumor weight, respectively). Mice that received 25 mg/kg DHP107 twice per week or 50 mg/kg DHP107 once per week per os had a significant decrease in tumor weight compared with vehicle-treated controls (p<0.01, both doses). CONCLUSION: Metronomic oral chemotherapy with DHP107 showed anti-tumor efficacy in vivo similar to IP paclitaxel in an orthotopic mouse model.
